Get all your news in one place.
100's of premium titles.
One app.
Start reading
MarketBeat
MarketBeat
Business
Leo Miller

Brutal 2025 for Sarepta—Analysts Still Call for 179% Upside

For Sarepta Therapeutics (NASDAQ: SRPT), 2025 has been nothing short of an unmitigated disaster. The firm owns the only Food and Drug Administration (FDA)-approved gene therapy for the treatment of Duchenne muscular dystrophy (DMD), known as ELEVIDYS. Since gaining approval in June 2023, Sarepta has generated over $1 billion in revenue from ELEVIDYS. However, that success has been massively overshadowed by key failures.

In 2025, multiple people treated with ELEVIDYS have died, causing shares to plunge. Overall, Sarepta shares are down by more than 85% in 2025, as of the Aug. 11 close. However, multiple Wall Street analysts seem to believe a huge recovery could be in store for Sarepta.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.